Contineum Therapeutics (CTNM) Payables (2023 - 2026)

Contineum Therapeutics' Payables history runs 4 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• In Q1 2026, Payables fell 58.98% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (down 58.98% YoY), while the FY2025 annual figure was $1.0 million, down 43.9% from the prior year.
• Payables was $1.5 million for Q1 2026 at Contineum Therapeutics, up from $1.0 million in the prior quarter.
• In the past five years, Payables ranged from a high of $3.6 million in Q1 2025 to a low of $570000.0 in Q1 2024.
• Historically, Payables has averaged $1.4 million across 4 years, with a median of $1.2 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Payables surged 539.47% in 2025, then slumped 58.98% in 2026.
• A 4-year view of Payables shows it stood at $635000.0 in 2023, then jumped by 185.2% to $1.8 million in 2024, then sank by 43.9% to $1.0 million in 2025, then soared by 47.15% to $1.5 million in 2026.
• The last three Payables figures came in at $1.5 million (Q1 2026), $1.0 million (Q4 2025), and $786000.0 (Q3 2025), per Business Quant data.